Bellevue Group Ag Insmed Inc Transaction History

Bellevue Group Ag

$5.02 Billion
Q4 2024

A detailed history of Bellevue Group Ag transactions in Insmed Inc stock. As of the latest transaction made, Bellevue Group Ag holds 258,483 shares of INSM stock, worth $19.4 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares

258,483

Previous 525,434 50.81%

Holding current value

$19.4 Million

Previous $38.4 Million 53.48%

% of portfolio

0.36%

Previous 0.65%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$66.29 - $76.63 $17.7 Million - $20.5 Million	-266,951 Reduced 50.81%	258,483 $17.8 Million
Q3 2024 Nov 14, 2024	SELL	$62.0 - $79.01 $30.8 Million - $39.2 Million	-496,266 Reduced 48.57%	525,434 $38.4 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $24.6 Million - $78.1 Million	-1,120,143 Reduced 52.3%	1,021,700 $68.5 Million
Q1 2024 May 15, 2024	SELL	$25.72 - $29.94 $3.84 Million - $4.46 Million	-149,115 Reduced 6.51%	2,141,843 $58.1 Million
Q4 2023 Feb 14, 2024	SELL	$23.42 - $31.74 $20.4 Million - $27.7 Million	-871,777 Reduced 27.56%	2,290,958 $71 Million
Q3 2023 Nov 14, 2023	SELL	$19.86 - $26.93 $2.74 Million - $3.72 Million	-138,176 Reduced 4.19%	3,162,735 $79.9 Million
Q2 2023 Aug 14, 2023	BUY	$16.44 - $21.1 $128,379 - $164,769	7,809 Added 0.24%	3,300,911 $69.6 Million
Q1 2023 May 15, 2023	BUY	$16.26 - $21.73 $258,452 - $345,398	15,895 Added 0.49%	3,293,102 $56.1 Million
Q4 2022 Feb 14, 2023	BUY	$16.98 - $23.15 $1.06 Million - $1.45 Million	62,503 Added 1.94%	3,277,207 $65.5 Million
Q3 2022 Nov 14, 2022	SELL	$20.88 - $28.21 $8.5 Million - $11.5 Million	-406,858 Reduced 11.23%	3,214,704 $69.2 Million
Q2 2022 Aug 11, 2022	BUY	$17.07 - $25.71 $1.19 Million - $1.79 Million	69,786 Added 1.96%	3,621,562 $71.4 Million
Q1 2022 May 13, 2022	BUY	$20.42 - $28.13 $631,284 - $869,638	30,915 Added 0.88%	3,551,776 $83.5 Million
Q4 2021 Feb 10, 2022	BUY	$25.89 - $33.45 $3.5 Million - $4.52 Million	135,216 Added 3.99%	3,520,861 $95.9 Million
Q3 2021 Nov 12, 2021	BUY	$22.46 - $29.47 $5.95 Million - $7.8 Million	264,744 Added 8.48%	3,385,645 $93.2 Million
Q2 2021 Aug 12, 2021	BUY	$24.17 - $36.01 $15.6 Million - $23.2 Million	643,735 Added 25.99%	3,120,901 $88.8 Million
Q1 2021 May 12, 2021	BUY	$32.28 - $44.3 $27.8 Million - $38.1 Million	860,166 Added 53.2%	2,477,166 $84.4 Million
Q4 2020 Feb 16, 2021	BUY	$31.45 - $40.54 $12.5 Million - $16.1 Million	396,831 Added 32.52%	1,617,000 $53.8 Million
Q3 2020 Nov 16, 2020	SELL	$26.0 - $34.5 $6.14 Million - $8.14 Million	-236,005 Reduced 16.21%	1,220,169 $39.2 Million
Q2 2020 Aug 13, 2020	SELL	$14.11 - $29.42 $2.22 Million - $4.63 Million	-157,296 Reduced 9.75%	1,456,174 $40.1 Million
Q1 2020 May 14, 2020	BUY	$13.63 - $33.98 $407,673 - $1.02 Million	29,910 Added 1.89%	1,613,470 $25.9 Million
Q4 2019 Feb 14, 2020	BUY	$16.12 - $24.98 $6.32 Million - $9.79 Million	392,080 Added 32.91%	1,583,560 $37.8 Million
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $8.85 Million - $14.7 Million	571,021 Added 92.03%	1,191,480 $21 Million
Q2 2019 Aug 14, 2019	SELL	$23.0 - $32.19 $896,425 - $1.25 Million	-38,975 Reduced 5.91%	620,459 $15.9 Million
Q1 2019 May 15, 2019	SELL	$13.91 - $31.15 $2.08 Million - $4.66 Million	-149,712 Reduced 18.5%	659,434 $19.2 Million
Q4 2018 Feb 12, 2019	BUY	$11.6 - $18.7 $2.82 Million - $4.54 Million	242,845 Added 42.88%	809,146 $10.6 Million
Q3 2018 Nov 13, 2018	BUY	$18.95 - $28.08 $2.7 Million - $3.99 Million	142,250 Added 33.55%	566,301 $11.5 Million
Q2 2018 Aug 07, 2018	BUY	$20.0 - $29.72 $1.79 Million - $2.66 Million	89,562 Added 26.78%	424,051 $10 Million
Q1 2018 May 09, 2018	BUY	$21.69 - $32.99 $7.26 Million - $11 Million	334,489 New	334,489 $7.53 Million

Others Institutions Holding INSM

# of Institutions

498

Shares Held

189M

Call Options Held

3.21M

Put Options Held

2.72M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10.2B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Insmed Inc Transaction History